Pyxis Oncology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Several Biotechnology Value Funds and Mark N. Lampert have jointly filed a Schedule 13G, disclosing beneficial ownership of Pyxis Oncology, Inc. common stock and warrants.
NASDAQ
GordonMD Global Investments LP and affiliated entities report beneficial ownership of 10,024,909 shares, representing 12.1% of Pyxis Oncology, Inc.'s common stock.
NASDAQ
Laurion Capital Management LP and its co-managing members have disclosed a 7.72% beneficial ownership stake in Pyxis Oncology, Inc., totaling 4,796,479 shares of common stock.
NASDAQ
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported a 1.3% beneficial ownership stake in Pyxis Oncology, Inc. as of September 30, 2025.
NASDAQ
GordonMD Global Investments LP and its affiliates have reported a 6.2% beneficial ownership stake in Pyxis Oncology, Inc., totaling 3,834,740 shares.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 1.5% Passive Stake in Pyxis Oncology
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.5% passive beneficial ownership stake in Pyxis Oncology, Inc. as of June 30, 2025.
NASDAQ
Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a passive beneficial ownership of 5.7% in Pyxis Oncology, Inc.'s common stock.
NASDAQ
Millennium Management LLC and its affiliated entities have filed an amended Schedule 13G, disclosing a reduction in their passive beneficial ownership of Pyxis Oncology, Inc.'s common stock to 4.0% as of March 31, 2025.
NASDAQ
Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC have filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.6% in Pyxis Oncology, Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Deep Track Capital Divests Entire Stake in Pyxis Oncology, Filing Shows 0% Beneficial Ownership
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G indicating they no longer hold any beneficial ownership in Pyxis Oncology, Inc. as of December 31, 2024.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.6% beneficial ownership stake in Pyxis Oncology, Inc. as of December 31, 2024.